NO20021640L - Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba - Google Patents

Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba

Info

Publication number
NO20021640L
NO20021640L NO20021640A NO20021640A NO20021640L NO 20021640 L NO20021640 L NO 20021640L NO 20021640 A NO20021640 A NO 20021640A NO 20021640 A NO20021640 A NO 20021640A NO 20021640 L NO20021640 L NO 20021640L
Authority
NO
Norway
Prior art keywords
carnitine
prevention
treatment
circulatory diseases
extracts
Prior art date
Application number
NO20021640A
Other languages
English (en)
Other versions
NO20021640D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20021640D0 publication Critical patent/NO20021640D0/no
Publication of NO20021640L publication Critical patent/NO20021640L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En sammensetning som er egnet til forebygging og/eller behandling av kretsløssykdommer ved både perifert og cerebralt nivå, og som dermed kan foreligge som et kosttilskudd, et diett-tilskudd eller som en aktuell medisin, som omfatter som karakteriserende aktive ingredienser: (a) et kamitin valgt fra gruppen bestående av acetyl L-karnitin og propionyl L- kamitin eller et farmakologisk akseptabelt salt derav eller blandinger derav; og (b) et ekstrakt av Ginkgo biloba eller en eller flere av ginkgolidene isolert fra Ginkgo biloba eller blandinger derav, er beskrevet.
NO20021640A 1999-10-08 2002-04-05 Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba NO20021640L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000618A IT1306722B1 (it) 1999-10-08 1999-10-08 Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
PCT/IT2000/000391 WO2001026666A2 (en) 1999-10-08 2000-10-02 Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba

Publications (2)

Publication Number Publication Date
NO20021640D0 NO20021640D0 (no) 2002-04-05
NO20021640L true NO20021640L (no) 2002-05-29

Family

ID=11406992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021640A NO20021640L (no) 1999-10-08 2002-04-05 Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba

Country Status (21)

Country Link
US (1) US6641849B1 (no)
EP (1) EP1218022B1 (no)
AR (1) AR025790A1 (no)
AT (1) ATE237341T1 (no)
AU (1) AU780643B2 (no)
CA (1) CA2386770C (no)
CZ (1) CZ20021062A3 (no)
DE (1) DE60002226T2 (no)
DK (1) DK1218022T3 (no)
ES (1) ES2195939T3 (no)
HU (1) HU227042B1 (no)
IL (1) IL148963A0 (no)
IT (1) IT1306722B1 (no)
MX (1) MXPA02003501A (no)
NO (1) NO20021640L (no)
PL (1) PL199996B1 (no)
PT (1) PT1218022E (no)
SK (1) SK4052002A3 (no)
TN (1) TNSN00186A1 (no)
TR (1) TR200200948T2 (no)
WO (1) WO2001026666A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
IL157367A0 (en) * 2001-03-09 2004-02-19 Nestle Sa Composition improving age-related physiological deficits and increasing longevity
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
KR20070020036A (ko) 2004-05-18 2007-02-16 브라이트 퓨처 파마수티컬 라보라토리스 리미티드 수면 장애를 위한 조성물
GB0411166D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
CZ308282B6 (cs) * 2010-08-05 2020-04-15 Výzkumný ústav živočišné výroby, v. v. i. Krmný doplněk pro zvýšení libida kanců
CN102783568B (zh) * 2012-08-29 2014-05-14 山东中医药大学 一种饲料添加剂
ES2666836T3 (es) * 2014-06-04 2018-05-08 Alfasigma S.P.A. Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
DE9318632U1 (de) * 1993-12-06 1995-04-06 Emsa-Werke Wulf GmbH & Co, 48282 Emsdetten Vorrichtung zum Aufnehmen von Folienrollen
US6221356B1 (en) * 1996-12-13 2001-04-24 Viva America Marketing, Inc. Method of preparation of biologically active Ginkgo biloba product
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.

Also Published As

Publication number Publication date
IL148963A0 (en) 2002-11-10
NO20021640D0 (no) 2002-04-05
AU780643B2 (en) 2005-04-07
PL199996B1 (pl) 2008-11-28
US6641849B1 (en) 2003-11-04
WO2001026666A3 (en) 2001-09-13
WO2001026666A2 (en) 2001-04-19
MXPA02003501A (es) 2002-09-02
CA2386770A1 (en) 2001-04-19
IT1306722B1 (it) 2001-10-02
HUP0203449A3 (en) 2005-04-28
DE60002226T2 (de) 2004-03-04
AU7945600A (en) 2001-04-23
PT1218022E (pt) 2003-09-30
PL354413A1 (en) 2004-01-12
HU227042B1 (en) 2010-05-28
DK1218022T3 (da) 2003-08-11
EP1218022A2 (en) 2002-07-03
AR025790A1 (es) 2002-12-11
EP1218022B1 (en) 2003-04-16
DE60002226D1 (de) 2003-05-22
SK4052002A3 (en) 2002-09-10
CA2386770C (en) 2009-09-08
TR200200948T2 (tr) 2002-10-21
TNSN00186A1 (fr) 2005-11-10
ATE237341T1 (de) 2003-05-15
HUP0203449A2 (hu) 2003-02-28
ES2195939T3 (es) 2003-12-16
ITRM990618A1 (it) 2001-04-08
ITRM990618A0 (it) 1999-10-08
CZ20021062A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
WO1999066913A3 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
AU2014324608B2 (en) Nutraceutical compositon for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation
ATE311874T1 (de) Kosmetische, diätetische oder pharmazeutische zusammensetzung die thioctsäure und cystein enthalten
JP2002527389A5 (no)
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
RU2336087C2 (ru) Применение частей опунции и/или экстрактов из нее для лечения депрессий
JP2002524419A (ja) 哺乳類において精神能力を改善するための組成物
Singh et al. An Overview of Dietary Flavonoids as a Nutraceutical Nanoformulation Approach to Life-threatening Diseases
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
IT1307278B1 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
CA2440333A1 (en) Process for obtention of decoctions of vitis labrusca and vitis vinifera skins
WO2003022218A3 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
JP4584453B2 (ja) バイオフラボノールの混合物を含む組成物
TR200200015T2 (tr) L-Karnitin ve türevleri ile crataegus ekstreleri içeren kardiyoaktif bileşim
Seniuk et al. Experimental studies on the hepatoprotective properties of herbal substances
EP1232748A4 (en) SUBSTITUTED NITROBENZENE-LIKE DERIVATIVE PRODUCT AS A MEDICINAL PRODUCT OR OTHER EFFICIENT PRODUCTS
BR0316441A (pt) Utilização de um composto, composto e medicamento
JP2005229855A (ja) 食品組成物
Bedard Hawthorn: should patients self-medicate to treat CHF?
MXPA06004673A (en) Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application